<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38892659</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1727</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu16111727</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Short-chain fatty acids (SCFAs) have been reported to be associated with the pathogenesis of irritable bowel syndrome (IBS), but the results are conflicting.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Here, a systematic review of case-control studies detecting fecal SCFAs in IBS patients compared with healthy controls (HCs) and self-controlled studies or randomized controlled trials (RCTs) investigating fecal SCFA alterations after interventions were identified from several databases.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">A systematic search of databases (PubMed, Web of Science, and Embase) identified 21 studies published before 24 February 2023. Data extractions: Three independent reviewers completed the relevant data extraction.</AbstractText><AbstractText Label="DATA ANALYSIS" NlmCategory="METHODS">It was found that the fecal propionate concentration in IBS patients was significantly higher than that in HCs, while the acetate proportion was significantly lower. Low-FODMAP diets significantly reduced the fecal propionate concentration in the IBS patients while fecal microbiota transplantation and probiotic administration did not significantly change the fecal propionate concentration or acetate proportion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results suggested that the fecal propionate concentration and acetate proportion could be used as biomarkers for IBS diagnosis. A low-FODMAP diet intervention could potentially serve as a treatment for IBS while FMT and probiotic administration need more robust trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Functional Food from Plant Resources, College of Food Science &amp; Nutritional Engineering, China Agricultural University, Beijing 100083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhenliang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Functional Food from Plant Resources, College of Food Science &amp; Nutritional Engineering, China Agricultural University, Beijing 100083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jiayin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Key Laboratory of Functional Food from Plant Resources, College of Food Science &amp; Nutritional Engineering, China Agricultural University, Beijing 100083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5435-5905</Identifier><AffiliationInfo><Affiliation>Beijing Key Laboratory of Functional Food from Plant Resources, College of Food Science &amp; Nutritional Engineering, China Agricultural University, Beijing 100083, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011422">Propionates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="Y">Feces</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005232" MajorTopicYN="Y">Fatty Acids, Volatile</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011422" MajorTopicYN="N">Propionates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FMT</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">low-FODMAP diet</Keyword><Keyword MajorTopicYN="N">short-chain fatty acids</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare with regard to the content of this systematic review.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38892659</ArticleId><ArticleId IdType="pmc">PMC11174707</ArticleId><ArticleId IdType="doi">10.3390/nu16111727</ArticleId><ArticleId IdType="pii">nu16111727</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Agrawal A., Aziz I., Farmer A.D., Eugenicos M.P., et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70:1214&#x2013;1240. doi: 10.1136/gutjnl-2021-324598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweig A., Schindler V., Becker A.S., van Maren A., Pohl D. Higher prevalence of joint hypermobility in constipation predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2018;30:e13353. doi: 10.1111/nmo.13353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13353</ArticleId><ArticleId IdType="pubmed">29687534</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M., Lembo A. Microbiome and Its Role in Irritable Bowel Syndrome. Dig. Dis. Sci. 2020;65:829&#x2013;839. doi: 10.1007/s10620-020-06109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06109-5</ArticleId><ArticleId IdType="pubmed">32026278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W.D., Kurlander J., Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015;313:949&#x2013;958. doi: 10.1001/jama.2015.0954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.0954</ArticleId><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamieva Z., Poluektova E., Svistushkin V., Sobolev V., Shifrin O., Guarner F., Ivashkin V. Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations? World J. Gastroenterol. 2022;28:1204&#x2013;1219. doi: 10.3748/wjg.v28.i12.1204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i12.1204</ArticleId><ArticleId IdType="pmc">PMC8968486</ArticleId><ArticleId IdType="pubmed">35431513</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont H.L. Review article: Evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment. Pharmacol. Ther. 2014;39:1033&#x2013;1042. doi: 10.1111/apt.12728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12728</ArticleId><ArticleId IdType="pubmed">24665829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassinen A., Krogius-Kurikka L., M&#xe4;kivuokko H., Rinttil&#xe4; T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24&#x2013;33. doi: 10.1053/j.gastro.2007.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.04.005</ArticleId><ArticleId IdType="pubmed">17631127</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoodi I., Alshanqeeti A.S., Alyamani E.J., AlLehibi A.A., Alqutub A.N., Alsayari K.N., Alomair A.O. Microbial dysbiosis in irritable bowel syndrome: A single-center metagenomic study in Saudi Arabia. JGH Open. 2020;4:649&#x2013;655. doi: 10.1002/jgh3.12313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12313</ArticleId><ArticleId IdType="pmc">PMC7411548</ArticleId><ArticleId IdType="pubmed">32782952</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:521&#x2013;530.e248. doi: 10.1111/j.1365-2982.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC3975596</ArticleId><ArticleId IdType="pubmed">22339879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia B., Iribarren C., Magnusson M.K., Sundin J., Clevers E., Savolainen O., Ross A.B., T&#xf6;rnblom H., Simr&#xe9;n M., &#xd6;hman L. A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. Cells. 2021;10:1459. doi: 10.3390/cells10061459.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061459</ArticleId><ArticleId IdType="pmc">PMC8230381</ArticleId><ArticleId IdType="pubmed">34200772</ArticleId></ArticleIdList></Reference><Reference><Citation>He J., Zhang P., Shen L., Niu L., Tan Y., Chen L., Zhao Y., Bai L., Hao X., Li X., et al. Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism. Int. J. Mol. Sci. 2020;21:6356. doi: 10.3390/ijms21176356.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21176356</ArticleId><ArticleId IdType="pmc">PMC7503625</ArticleId><ArticleId IdType="pubmed">32887215</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar M., Chen Y., Ma Z., Zhang X., Shi D., Khan J.A., Liu H. Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim. Nutr. 2022;8:350&#x2013;360. doi: 10.1016/j.aninu.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aninu.2021.11.005</ArticleId><ArticleId IdType="pmc">PMC9040132</ArticleId><ArticleId IdType="pubmed">35510031</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Gallausiaux C., Marinelli L., Blotti&#xe8;re H.M., Larraufie P., Lapaque N. SCFA: Mechanisms and functional importance in the gut. Proc. Nutr. Soc. 2021;80:37&#x2013;49. doi: 10.1017/s0029665120006916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0029665120006916</ArticleId><ArticleId IdType="pubmed">32238208</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciume G.D., Berti G., Lambiase C., Paglianiti I., Villanacci V., Rettura F., Grosso A., Ricchiuti A., Bortoli N., Usai Satta P., et al. Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights. J. Clin. Med. 2023;12:5787. doi: 10.3390/jcm12185787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12185787</ArticleId><ArticleId IdType="pmc">PMC10531598</ArticleId><ArticleId IdType="pubmed">37762728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010;22:512-e115. doi: 10.1111/j.1365-2982.2009.01427.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01427.x</ArticleId><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Treem W.R., Ahsan N., Kastoff G., Hyams J.S. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: In vitro studies of carbohydrate fermentation. J. Pediatr. Gastroenterol. Nutr. 1996;23:280&#x2013;286. doi: 10.1097/00005176-199610000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-199610000-00013</ArticleId><ArticleId IdType="pubmed">8890079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Z., Zhuang X., Luo M., Yin W., Xiong L. The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2020;20:73. doi: 10.1186/s12876-020-01212-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-020-01212-3</ArticleId><ArticleId IdType="pmc">PMC7077160</ArticleId><ArticleId IdType="pubmed">32178625</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C.R., Tang B., Shi Y.Z., Peng W.Y., Ye K., Tao Q.F., Yu S.G., Zheng H., Chen M. Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review with Network Meta-analysis. Front. Pharmacol. 2022;13:853011. doi: 10.3389/fphar.2022.853011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.853011</ArticleId><ArticleId IdType="pmc">PMC8959572</ArticleId><ArticleId IdType="pubmed">35355730</ArticleId></ArticleIdList></Reference><Reference><Citation>Varj&#xfa; P., Farkas N., Hegyi P., Garami A., Szab&#xf3; I., Ill&#xe9;s A., Solym&#xe1;r M., Vincze &#xc1;., Balask&#xf3; M., P&#xe1;r G., et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: A meta-analysis of clinical studies. PLoS ONE. 2017;12:e0182942. doi: 10.1371/journal.pone.0182942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182942</ArticleId><ArticleId IdType="pmc">PMC5555627</ArticleId><ArticleId IdType="pubmed">28806407</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Yang P., Zhang L., Hou X. A Low-FODMAP Diet Improves the Global Symptoms and Bowel Habits of Adult IBS Patients: A Systematic Review and Meta-Analysis. Front. Nutr. 2021;8:683191. doi: 10.3389/fnut.2021.683191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2021.683191</ArticleId><ArticleId IdType="pmc">PMC8417072</ArticleId><ArticleId IdType="pubmed">34490319</ArticleId></ArticleIdList></Reference><Reference><Citation>Myneedu K., Deoker A., Schmulson M.J., Bashashati M. Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. United Eur. Gastroenterol. J. 2019;7:1033&#x2013;1041. doi: 10.1177/2050640619866990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640619866990</ArticleId><ArticleId IdType="pmc">PMC6794695</ArticleId><ArticleId IdType="pubmed">31662860</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010;25:603&#x2013;605. doi: 10.1007/s10654-010-9491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Savovi&#x107; J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.Y., Corbett M.S., Eldridge S.M., et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M., Li T., Page M.J., Chandler J., Welch V.A., Higgins J.P., Thomas J. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev. 2019;10:Ed000142. doi: 10.1002/14651858.Ed000142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.Ed000142</ArticleId><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson D. The power of the standard test for the presence of heterogeneity in meta-analysis. Stat. Med. 2006;25:2688&#x2013;2699. doi: 10.1002/sim.2481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2481</ArticleId><ArticleId IdType="pubmed">16374903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustoft T.N., Hausken T., Ystad S.O., Valeur J., Brokstad K., Hatlebakk J.G., Lied G.A. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2017;29:e12969. doi: 10.1111/nmo.12969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12969</ArticleId><ArticleId IdType="pubmed">27747984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargari G., Taverniti V., Gardana C., Cremon C., Canducci F., Pagano I., Barbaro M.R., Bellacosa L., Castellazzi A.M., Valsecchi C., et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ. Microbiol. 2018;20:3201&#x2013;3213. doi: 10.1111/1462-2920.14271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1462-2920.14271</ArticleId><ArticleId IdType="pubmed">29749705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Feng L., Wang X., Fox M., Luo L., Du L., Chen B., Chen X., He H., Zhu S., et al. Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: A parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes. Am. J. Clin. Nutr. 2021;113:1531&#x2013;1545. doi: 10.1093/ajcn/nqab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqab005</ArticleId><ArticleId IdType="pubmed">33740048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H., Guo Q., Wen Z., Tan S., Chen J., Lin L., Chen P., He J., Wen J., Chen Y. The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors. Microb. Cell Fact. 2021;20:233. doi: 10.1186/s12934-021-01720-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12934-021-01720-1</ArticleId><ArticleId IdType="pmc">PMC8715582</ArticleId><ArticleId IdType="pubmed">34963452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredericks E., Theunissen R., Roux S. Short chain fatty acids and monocarboxylate transporters in irritable bowel syndrome. Turk. J. Gastroenterol. 2020;31:840&#x2013;847. doi: 10.5152/tjg.2020.19856.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2020.19856</ArticleId><ArticleId IdType="pmc">PMC7928259</ArticleId><ArticleId IdType="pubmed">33625995</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale H.F., Jensen C., Hausken T., Valeur J., Hoff D.A.L., Lied G.A. Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients. 2019;11:1635. doi: 10.3390/nu11071635.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11071635</ArticleId><ArticleId IdType="pmc">PMC6682970</ArticleId><ArticleId IdType="pubmed">31319590</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta A., Camilleri M., Shin A., Linker Nord S., O&#x2019;Neill J., Gray A.V., Lueke A.J., Donato L.J., Burton D.D., Szarka L.A., et al. Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clin. Transl. Gastroenterol. 2016;7:e173. doi: 10.1038/ctg.2016.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ctg.2016.32</ArticleId><ArticleId IdType="pmc">PMC4893683</ArticleId><ArticleId IdType="pubmed">27228404</ArticleId></ArticleIdList></Reference><Reference><Citation>Remes-Troche J.M., Taboada-Liceaga H., Gill S., Amieva-Balmori M., Rossi M., Hern&#xe1;ndez-Ram&#xed;rez G., Garc&#xed;a-Mazcorro J.F., Whelan K. Nopal fiber (Opuntia ficus-indica) improves symptoms in irritable bowel syndrome in the short term: A randomized controlled trial. Neurogastroenterol. Motil. 2021;33:e13986. doi: 10.1111/nmo.13986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13986</ArticleId><ArticleId IdType="pubmed">32935904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United Eur. Gastroenterol. J. 2018;6:604&#x2013;613. doi: 10.1177/2050640617736478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640617736478</ArticleId><ArticleId IdType="pmc">PMC5987284</ArticleId><ArticleId IdType="pubmed">29881616</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Rossi M., Kaminski T., Dimidi E., Ralph F.S.E., Wilson B., Martin L.D., Louis P., Lomer M.C.E., Irving P.M., et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol. Motil. 2022;34:e14241. doi: 10.1111/nmo.14241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14241</ArticleId><ArticleId IdType="pubmed">34431172</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Valeur J., Hausken T., Gunnar Hatlebakk J. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2021;33:e13983. doi: 10.1111/nmo.13983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13983</ArticleId><ArticleId IdType="pmc">PMC7900992</ArticleId><ArticleId IdType="pubmed">32945066</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Casen C., Valeur J., Hausken T., Hatlebakk J.G. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World J. Gastroenterol. 2021;27:2219&#x2013;2237. doi: 10.3748/wjg.v27.i18.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i18.2219</ArticleId><ArticleId IdType="pmc">PMC8117742</ArticleId><ArticleId IdType="pubmed">34025075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mujagic Z., Jonkers D., Ludidi S., Keszthelyi D., Hesselink M.A., Weerts Z., Kievit R.N., Althof J.F., Leue C., Kruimel J.W., et al. Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2017;29:e13137. doi: 10.1111/nmo.13137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13137</ArticleId><ArticleId IdType="pubmed">28675524</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton C., Fowler D.P., Turner C., Jia W., Whitehead R.N., Griffiths L., Dawson C., Waring R.H., Ramsden D.B., Cole J.A., et al. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm. Bowel Dis. 2013;19:2069&#x2013;2078. doi: 10.1097/MIB.0b013e31829a91f6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0b013e31829a91f6</ArticleId><ArticleId IdType="pubmed">23867873</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Jia Q., Zhang L., Wang Z., Zhu S., Wang X., Liu Y., Li M., Zhang J., Wang X., et al. Multiomics Study of Gut Bacteria and Host Metabolism in Irritable Bowel Syndrome and Depression Patients. Front. Cell. Infect. Microbiol. 2020;10:580980. doi: 10.3389/fcimb.2020.580980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.580980</ArticleId><ArticleId IdType="pmc">PMC7658686</ArticleId><ArticleId IdType="pubmed">33194817</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastwood M.A., Walton B.A., Brydon W.G., Anderson J.R. Faecal weight, constituents, colonic motility, and lactose tolerance in the irritable bowel syndrome. Digestion. 1984;30:7&#x2013;12. doi: 10.1159/000199085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000199085</ArticleId><ArticleId IdType="pubmed">6489646</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall G., Noor S.O., Ridgway K., Scovell L., Jamieson C., Johnson I.T., Colquhoun I.J., Kemsley E.K., Narbad A. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J. Proteome Res. 2011;10:4208&#x2013;4218. doi: 10.1021/pr2003598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr2003598</ArticleId><ArticleId IdType="pubmed">21761941</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y., Yamashita R., Kawashima J., Mori H., Kurokawa K., Fukuda S., Gotoh Y., Nakamura K., Hayashi T., Kasahara Y., et al. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J. Gastroenterol. 2022;57:748&#x2013;760. doi: 10.1007/s00535-022-01888-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-022-01888-2</ArticleId><ArticleId IdType="pmc">PMC9522833</ArticleId><ArticleId IdType="pubmed">35908139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Rijnaarts I., Hermes G.D.A., de Roos N.M., Witteman B.J.M., de Wit N.J.W., Govers C., Smidt H., Zoetendal E.G. Fecal Microbiota Signatures Are Not Consistently Related to Symptom Severity in Irritable Bowel Syndrome. Dig. Dis. Sci. 2022;67:5137&#x2013;5148. doi: 10.1007/s10620-022-07543-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-022-07543-3</ArticleId><ArticleId IdType="pmc">PMC9587953</ArticleId><ArticleId IdType="pubmed">35624331</ArticleId></ArticleIdList></Reference><Reference><Citation>Farup P.G., Rudi K., Hestad K. Faecal short-chain fatty acids&#x2014;A diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016;16:51. doi: 10.1186/s12876-016-0446-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0446-z</ArticleId><ArticleId IdType="pmc">PMC4847229</ArticleId><ArticleId IdType="pubmed">27121286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui H., Nishida A., Matsuda S., Kira F., Watanabe S., Kuriyama M., Kawakami K., Aikawa Y., Oda N., Arai K., et al. Usefulness of Machine Learning-Based Gut Microbiome Analysis for Identifying Patients with Irritable Bowels Syndrome. J. Clin. Med. 2020;9:2403. doi: 10.3390/jcm9082403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082403</ArticleId><ArticleId IdType="pmc">PMC7464323</ArticleId><ArticleId IdType="pubmed">32727141</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93&#x2013;100. doi: 10.1136/gutjnl-2014-307264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307264</ArticleId><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen P.B., Andersen J.R., Arffmann S., Krag E. Short-chain fatty acids and the irritable bowel syndrome: The effect of wheat bran. Scand. J. Gastroenterol. 1987;22:185&#x2013;192. doi: 10.3109/00365528708991878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365528708991878</ArticleId><ArticleId IdType="pubmed">3033815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Choi C.H., Temas D., Kim A., Maier D.M., Scott K., Galanko J.A., Ringel Y. Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. Am. J. Gastroenterol. 2015;110:1339&#x2013;1346. doi: 10.1038/ajg.2015.220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2015.220</ArticleId><ArticleId IdType="pmc">PMC4983766</ArticleId><ArticleId IdType="pubmed">26303129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar N.M., Duboc H., Kay G.L., Alam M.T., Wicaksono A.N., Covington J.A., Quince C., Kokkorou M., Svolos V., Palmieri L.J., et al. The pathophysiology of bile acid diarrhoea: Differences in the colonic microbiome, metabolome and bile acids. Sci. Rep. 2020;10:20436. doi: 10.1038/s41598-020-77374-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77374-7</ArticleId><ArticleId IdType="pmc">PMC7686486</ArticleId><ArticleId IdType="pubmed">33235223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q.H., Liu Z.J., Zhang L., Wei H., Song L.J., Zhu S.W., He M.B., Duan L.P. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients. J. Dig. Dis. 2021;22:246&#x2013;255. doi: 10.1111/1751-2980.12988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-2980.12988</ArticleId><ArticleId IdType="pmc">PMC8252430</ArticleId><ArticleId IdType="pubmed">33822477</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernia P., Latella G., Magliocca F.M., Mancuso G., Caprilli R. Seeking clues for a positive diagnosis of the irritable bowel syndrome. Eur. J. Clin. Investig. 1987;17:189&#x2013;193. doi: 10.1111/j.1365-2362.1987.tb01234.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.1987.tb01234.x</ArticleId><ArticleId IdType="pubmed">3113963</ArticleId></ArticleIdList></Reference><Reference><Citation>Waseem M.R., Shin A., Siwiec R., James-Stevenson T., Bohm M., Rogers N., Wo J., Waseem L., Gupta A., Jarrett M., et al. Associations of Fecal Short Chain Fatty Acids with Colonic Transit, Fecal Bile Acid, and Food Intake in Irritable Bowel Syndrome. Clin. Transl. Gastroenterol. 2023;14:e00541. doi: 10.14309/ctg.0000000000000541.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000541</ArticleId><ArticleId IdType="pmc">PMC9875959</ArticleId><ArticleId IdType="pubmed">36227781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W.X., Zhang Y., Qin G., Li K.M., Wei W., Li S.Y., Yao S.K. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome. World J. Gastroenterol. 2019;25:6416&#x2013;6429. doi: 10.3748/wjg.v25.i43.6416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i43.6416</ArticleId><ArticleId IdType="pmc">PMC6881512</ArticleId><ArticleId IdType="pubmed">31798278</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C.E., Anderson J.L., Barrett J.S., Muir J.G., Irving P.M., Whelan K. Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. J. Nutr. 2012;142:1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Codling C., O&#x2019;Mahony L., Shanahan F., Quigley E.M., Marchesi J.R. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig. Dis. Sci. 2010;55:392&#x2013;397. doi: 10.1007/s10620-009-0934-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0934-x</ArticleId><ArticleId IdType="pubmed">19693670</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2011;301:G799&#x2013;G807. doi: 10.1152/ajpgi.00154.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId><ArticleId IdType="pmc">PMC3220325</ArticleId><ArticleId IdType="pubmed">21737778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery I.B., Quigley E.M., &#xd6;hman L., Simr&#xe9;n M., O&#x2019;Toole P.W. The microbiota link to irritable bowel syndrome: An emerging story. Gut Microbes. 2012;3:572&#x2013;576. doi: 10.4161/gmic.21772.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.21772</ArticleId><ArticleId IdType="pmc">PMC3495796</ArticleId><ArticleId IdType="pubmed">22895081</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., McKenzie C., Potamitis M., Thorburn A.N., Mackay C.R., Macia L. The role of short-chain fatty acids in health and disease. Adv. Immunol. 2014;121:91&#x2013;119. doi: 10.1016/b978-0-12-800100-4.00003-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-800100-4.00003-9</ArticleId><ArticleId IdType="pubmed">24388214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura I., Inoue D., Maeda T., Hara T., Ichimura A., Miyauchi S., Kobayashi M., Hirasawa A., Tsujimoto G. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41) Proc. Natl. Acad. Sci. USA. 2011;108:8030&#x2013;8035. doi: 10.1073/pnas.1016088108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1016088108</ArticleId><ArticleId IdType="pmc">PMC3093469</ArticleId><ArticleId IdType="pubmed">21518883</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan N., Pluznick J.L. From microbe to man: The role of microbial short chain fatty acid metabolites in host cell biology. Am. J. Physiol. Cell Physiol. 2014;307:C979&#x2013;C985. doi: 10.1152/ajpcell.00228.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00228.2014</ArticleId><ArticleId IdType="pmc">PMC5243208</ArticleId><ArticleId IdType="pubmed">25273884</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashashati M., Rezaei N., Andrews C.N., Chen C.Q., Daryani N.E., Sharkey K.A., Storr M.A. Cytokines and irritable bowel syndrome: Where do we stand? Cytokine. 2012;57:201&#x2013;209. doi: 10.1016/j.cyto.2011.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2011.11.019</ArticleId><ArticleId IdType="pubmed">22178716</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.L., Wolin M.J. Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora. Appl. Environ. Microbiol. 1996;62:1589&#x2013;1592. doi: 10.1128/aem.62.5.1589-1592.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aem.62.5.1589-1592.1996</ArticleId><ArticleId IdType="pmc">PMC167932</ArticleId><ArticleId IdType="pubmed">8633856</ArticleId></ArticleIdList></Reference><Reference><Citation>Za&#x142;&#x119;ski A., Banaszkiewicz A., Walkowiak J. Butyric acid in irritable bowel syndrome. Prz. Gastroenterol. 2013;8:350&#x2013;353. doi: 10.5114/pg.2013.39917.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/pg.2013.39917</ArticleId><ArticleId IdType="pmc">PMC4027835</ArticleId><ArticleId IdType="pubmed">24868283</ArticleId></ArticleIdList></Reference><Reference><Citation>Furusawa Y., Obata Y., Fukuda S., Endo T.A., Nakato G., Takahashi D., Nakanishi Y., Uetake C., Kato K., Kato T., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446&#x2013;450. doi: 10.1038/nature12721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12721</ArticleId><ArticleId IdType="pubmed">24226770</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinen E., Rinttil&#xe4; T., Kajander K., M&#xe4;tt&#xf6; J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastroenterol. 2005;100:373&#x2013;382. doi: 10.1111/j.1572-0241.2005.40312.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.40312.x</ArticleId><ArticleId IdType="pubmed">15667495</ArticleId></ArticleIdList></Reference><Reference><Citation>Michl T., Jocic M., Heinemann A., Schuligoi R., Holzer P. Vagal afferent signaling of a gastric mucosal acid insult to medullary, pontine, thalamic, hypothalamic and limbic, but not cortical, nuclei of the rat brain. Pain. 2001;92:19&#x2013;27. doi: 10.1016/s0304-3959(00)00467-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3959(00)00467-x</ArticleId><ArticleId IdType="pubmed">11323123</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Cuesta-Zuluaga J., Mueller N.T., &#xc1;lvarez-Quintero R., Vel&#xe1;squez-Mej&#xed;a E.P., Sierra J.A., Corrales-Agudelo V., Carmona J.A., Abad J.M., Escobar J.S. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. Nutrients. 2018;11:51. doi: 10.3390/nu11010051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11010051</ArticleId><ArticleId IdType="pmc">PMC6356834</ArticleId><ArticleId IdType="pubmed">30591685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J.M., de Souza R., Kendall C.W., Emam A., Jenkins D.J. Colonic health: Fermentation and short chain fatty acids. J. Clin. Gastroenterol. 2006;40:235&#x2013;243. doi: 10.1097/00004836-200603000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004836-200603000-00015</ArticleId><ArticleId IdType="pubmed">16633129</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M., Zhuang X., Tian Z., Xiong L. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: A systematic review and meta-analysis. BMC Gastroenterol. 2021;21:14. doi: 10.1186/s12876-020-01577-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-020-01577-5</ArticleId><ArticleId IdType="pmc">PMC7788881</ArticleId><ArticleId IdType="pubmed">33407171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q., Jia Q., Song L., Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine. 2019;98:e14513. doi: 10.1097/MD.0000000000014513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000014513</ArticleId><ArticleId IdType="pmc">PMC6408019</ArticleId><ArticleId IdType="pubmed">30762787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto S., Tatewaki M., Yamada T., Fujimiya M., Mantyh C., Voss M., Eubanks S., Harris M., Pappas T.N., Takahashi T. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003;284:R1269&#x2013;R1276. doi: 10.1152/ajpregu.00442.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00442.2002</ArticleId><ArticleId IdType="pubmed">12676748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nybacka S., Tornblom H., Josefsson A., Hreinsson J.P., Bohn L., Frandemark A., Weznaver C., Storsrud S., Simren M. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): A single-centre, single-blind, randomised controlled trial. Lancet Gastroenterol. Hepatol. 2024;9:507&#x2013;520. doi: 10.1016/S2468-1253(24)00045-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(24)00045-1</ArticleId><ArticleId IdType="pubmed">38643782</ArticleId></ArticleIdList></Reference><Reference><Citation>So D., Yao C.K., Gill P.A., Thwaites P.A., Ardalan Z.S., McSweeney C.S., Denman S.E., Chrimes A.F., Muir J.G., Berean K.J., et al. Detection of changes in regional colonic fermentation in response to supplementing a low FODMAP diet with dietary fibres by hydrogen concentrations, but not by luminal pH. Aliment. Pharmacol. Ther. 2023;58:417&#x2013;428. doi: 10.1111/apt.17629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.17629</ArticleId><ArticleId IdType="pmc">PMC10946934</ArticleId><ArticleId IdType="pubmed">37386938</ArticleId></ArticleIdList></Reference><Reference><Citation>So D., Loughman A., Staudacher H.M. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: A systematic review with meta-analysis. Am. J. Clin. Nutr. 2022;116:943&#x2013;952. doi: 10.1093/ajcn/nqac176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqac176</ArticleId><ArticleId IdType="pmc">PMC9535515</ArticleId><ArticleId IdType="pubmed">35728042</ArticleId></ArticleIdList></Reference><Reference><Citation>Eetemadi A., Tagkopoulos I. Methane and fatty acid metabolism pathways are predictive of Low-FODMAP diet efficacy for patients with irritable bowel syndrome. Clin. Nutr. 2021;40:4414&#x2013;4421. doi: 10.1016/j.clnu.2020.12.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.12.041</ArticleId><ArticleId IdType="pubmed">33504454</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Chen V.L., Steiner C.A., Berinstein J.A., Eswaran S., Waljee A.K., Higgins P.D.R., Owyang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 2019;114:1043&#x2013;1050. doi: 10.14309/ajg.0000000000000198.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000198</ArticleId><ArticleId IdType="pmc">PMC7257434</ArticleId><ArticleId IdType="pubmed">30908299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Lv L., Wang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front. Cell. Infect. Microbiol. 2022;12:827395. doi: 10.3389/fcimb.2022.827395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.827395</ArticleId><ArticleId IdType="pmc">PMC8919053</ArticleId><ArticleId IdType="pubmed">35295757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G., Eusebi L.H., Black C.J., Gasbarrini A., Cammarota G., Ford A.C. Systematic review with meta-analysis: Efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2019;50:240&#x2013;248. doi: 10.1111/apt.15330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15330</ArticleId><ArticleId IdType="pubmed">31136009</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFilipp Z., Bloom P.P., Torres Soto M., Mansour M.K., Sater M.R.A., Huntley M.H., Turbett S., Chung R.T., Chen Y.B., Hohmann E.L. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. N. Engl. J. Med. 2019;381:2043&#x2013;2050. doi: 10.1056/NEJMoa1910437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910437</ArticleId><ArticleId IdType="pubmed">31665575</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland L.V., Karakan T., Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine. 2021;41:101154. doi: 10.1016/j.eclinm.2021.101154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101154</ArticleId><ArticleId IdType="pmc">PMC8529205</ArticleId><ArticleId IdType="pubmed">34712929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>